摘要
目的探讨促性腺激素释放激素类似物(GnRHa)治疗特发性中枢性性早熟女童的疗效及对体质量指数、性腺轴激素水平的影响。方法选取2021年3月至2023年5月在开平市中心医院生长发育专科诊断和治疗的42例特发性中枢性性早熟女童作为研究对象,年龄(7.5±2.3)岁,病程(10.98±2.75)个月,均予以GnRHa治疗,以注射用醋酸曲普瑞林为主要治疗药物,肌肉注射,每28~32 d注射1次。第1、2、3针剂量均为3.75 mg(最大剂量不超过180μg/kg),个别体质量较高患儿可间隔21 d加强1针;于第3针治疗后第14天行GnRH简易激发试验,根据黄体生成素(LH)峰值结果调整剂量至80~100μg/kg(最大剂量不超过3.75 mg)。测量治疗前、治疗半年后患儿的身高、体质量、骨龄、预测成年终身高(FAH)等生长发育相关指标,比较治疗前后体质量指数的变化以及卵泡刺激素(FSH)、LH、雌二醇(E2)等激素水平的改变,观察治疗前后子宫容积、卵巢容积、卵泡直径的变化,记录不良反应发生情况。采用Wilcoxon符号秩和检验。结果治疗半年后,患儿第二性征明显抑制,其中8例患儿月经撤退,34例患儿乳房分期退缩;患儿的身高、体质量、骨龄、FAH均高于治疗前[131.1(8.7)cm比127.8(8.2)cm、29.5(6.9)kg比27.0(5.5)kg、9.4(1.7)岁比9.0(1.6)岁、157.4(3.7)cm比154.9(2.8)cm](Z=-5.648、-5.600、-5.713、-5.125,均P<0.001);体质量指数标准差分值(BMISDS)无明显变化[16.7(1.6)kg/m^(2)比16.5(1.4)kg/m^(2)](Z=-0.356,P=0.682);子宫容积、卵巢容积、卵泡直径均较治疗前缩小[2.1(1.6)ml比3.1(2.1)ml、1.2(0.9)ml比2.0(2.8)ml、3.0(1.3)mm比8.0(2.3)mm],差异均有统计学意义(Z=-5.646、-5.579、-5.622,均P<0.001)。第3针治疗后,E2水平、FSH激发峰值、LH激发峰值均较治疗前下降[36.5(10.0)pmol/L比80.0(44.8)pmol/L、2.6(3.6)U/L比13.3(9.3)U/L、0.7(0.3)U/L比12.9(11.6)U/L](均P<0.001)。治疗过程中1例患儿出现臀部脂肪纹,其余患儿在治疗过程中并未�
Objective To investigate the effect of gonadotropin-releasing hormone analogue(GnRHa)in the treatment of idiopathic central precocious puberty(ICPP)in girls and its effects on body mass index and gonadal axis hormone levels.Methods A total of 42 girls with ICPP diagnosed and treated in the growth and development department of Kaiping Central Hospital from March 2021 to May 2023,were selected as the study subjects.The age was(7.5±2.3)years old,and the duration of disease was(10.98±2.75)months.All children were treated with GnRHa,with triptorelin acetate for injection as the main therapeutic drug,intramuscular injection,every 28 to 32 days.The first,second,and third doses were 3.75 mg(the maximum dose was not more than 180μg/kg),and children with higher body mass could be strengthened with 1 injection at an interval of 21 days.The GnRH simple stimulation test was performed on the 14th day after the third injection,and the dose was adjusted to 80 to 100μg/kg according to the results of luteinizing hormone(LH)peak(the maximum dose was not more than 3.75 mg).Their growth and development-related indicators such as height,body mass,bone age,and final adult height(FAH)were measured before treatment and 6 months after treatment.The changes in body mass index(BMI)and hormone levels such as follicle stimulating hormone(FSH),LH,and estradiol(E2)before and after treatment were compared.The changes in uterine volume,ovarian volume,and follicle diameter before and after treatment were observed,and the occurrence of adverse reactions was recorded.Wilcoxon signed rank sum test was used.Results After 6 months of treatment,the secondary sexual characteristics of the children were significantly suppressed,including 8 children with menstrual withdrawal and 34 children with staged breast withdrawal.After 6 months of treatment,the height,body mass,bone age,and FAH of the children were all higher than those before treatment[131.1(8.7)cm vs.127.8(8.2)cm,29.5(6.9)kg vs.27.0(5.5)kg,9.4(1.7)years vs.9.0(1.6)years,157.4(3.7)cm vs.154.9(2
作者
余艳媚
余淑娟
陈清凤
陈雪冰
Yu Yanmei;Yu Shujuan;Chen Qingfeng;Chen Xuebing(Department of Pediatrics,Kaiping Central Hospital,Kaiping 529300,China)
出处
《国际医药卫生导报》
2024年第10期1707-1711,共5页
International Medicine and Health Guidance News
基金
江门市科学技术局计划(2022YL10011)。
